期刊
DRUG DELIVERY
卷 28, 期 1, 页码 499-509出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10717544.2021.1892242
关键词
Amphotericin B; PLGA– PEG– PLGA; intrathecal injection; cryptococcal meningitis; sustained release
资金
- Shanghai Municipal Key Clinical Specialty [shslczdzk01001]
The study synthesized AMB-loaded thermogel for the treatment of cryptococcal meningitis, demonstrating its sustained release, reduced neurotoxicity, and improved therapeutic effect compared to traditional AMB solution, indicating the potential of the PLGA-PEG-PLGA thermogel as a biocompatible carrier for intrathecal drug delivery.
Cryptococcal meningitis is a fungal infectious disease with a poor prognosis and high mortality. Amphotericin B (AMB) is the first choice for the treatment of cryptococcal meninges. The blood-brain barrier (BBB) is the major barrier for the effective delivery of drugs to the brain. In this study, AMB was incorporated in a thermosensitive gel for intrathecal injection. We first synthesized AMB-loaded thermogel, investigated its in vitro cumulative release, and in vivo neurotoxicity, and therapeutic effect. The thermosensitive gel was comprised of 25 wt% poly (lactic acid-co-glycolic acid)-poly (ethylene glycol)-poly (lactic acid-co-glycolic acid) (PLGA-PEG-PLGA) triblock polymer aqueous solution. The AMB loaded in the thermosensitive gel (AMB in gel) had low viscosity at low temperature and resulted in the formation of a non-flowing gel at 37 degrees C (physiological temperature). AMB loading in gel sustained its release for 36 days and the in vitro cumulative release rate was satisfactory. Compared with the AMB solution, intrathecal administration of AMB in gel could reduce the neurovirulence of AMB and get a better treatment effect. The findings of the current study show that the injectable PLGA-PEG-PLGA thermogel is a biocompatible carrier for the delivery of drugs into the intrathecal.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据